Product Quality Review: Overview and Feedback from Inspection

Similar documents
Product quality reviews

DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW

Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers

Product quality review for listed Complementary Medicines

HACCP audit checklist

Annual product quality review: Guidance for industry by regulatory perspective

Self-Inspection and its potential benefits via ICH Q9 & Q10

Materials Management Traceability, CEPs and managing non-conforming sites

Wholesaling & Distribution & the GMPs

Wholesaling & Distribution & the GMPs

Deficiencies found in Inspections and QP Responsibilities

Technical updates medicines inspections: Finished Pharmaceutical Products (FPP)

Primary Distribution Activities

Annex 4. Guidance on good manufacturing practices: inspection report. Background

Inspection of API Manufacturers & Update on Registration Process

PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013.

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS

Common deficiencies/ hot topics

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer

Quality Assessment & GMP Similarities & Differences

Change Control Overview

Outsourcing - managing risks and opportunities over which you now have less control

Safeguarding public health. Deficiency Database Figures April June 2009

STANDARD OPERATING PROCEDURE TEAM INSPECTIONS

Guidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.

Overview of Regulatory Requirements for API and Formulations

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

EudraLex. Part I1 Chapter 6: Quality Control

Compliance with the GMP Standard in the International Level

A Compilation of WHO GMP Audit Points

GMP for ATMP. Advanced Therapy Medicinal Products Key2Compliance AB

Introduction to Medicines Inspections Technical Updates:

ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua

QUALITY MANUAL QM0492 ISO SUPPLEMENT III

Quality Risk Management. of the GDP Supply Chain. Dr Cormac Dalton Inspector. Crowne Plaza Hotel, 25/2/2010. Date 22-Feb-10 Slide 1

Quality Risk Management John Montalto Manager Training PharmOut Pty Ltd

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)

Quality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017

MEASURE FOR MEASURE: QUALITY METRICS

Overview of Draft API Standard 20M

Contents. Contents (13) 1 Production (23)

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

The Pharmacovigilance Quality System. What is it?

Testo Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance

The APIC Audit Programme Version 5, July 2017

Prequalification of Medicines Programme

Most Common Deficiencies Found. Dr Florence Benoit-Guyod Head of the inspection section Certification of Substances Department

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

WARNING LETTER AUG 3, 2016

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Wilson-Hurd ATF Quality Manual

Update to the Manufacturing Principles for Medicinal Products

Lifecycle Product Quality Risk Management

Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer

ICH Quality Implementation Working Group POINTS TO CONSIDER

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

A COMPARATIVE FRAMEWORK BETWEEN NEW PRODUCT & LEGACY PRODUCT PROCESS VALIDATION

WHO GMP for Pharmaceutical Products: Main Principles

Process Capability and relationship to Quality management

Inspection Hot Topics

Impact of EU GMPs on Australian GMP. Trevor Schoerie PharmOut

IDT Australia Ltd. 5/23/18

QUALITY MANUAL. This document defines the requirements, processes, structure and documentation for the Teledyne DGO Quality Management System.

AAMI Quality Systems White Paper

Enabling Improvement through the Product Lifecycle: Change Management within a PQS

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Q10 PHARMACEUTICAL QUALITY SYSTEM

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU

Regulatory Update. Paul Sexton. QP Forum

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL

Strategies to Revise Quality Policy and Quality Objectives. Eileen Cortes February 22, 2017

Developing an Internal Quality Auditing Program

WHO-PQP GMP Inspections: Updates

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Vendor Qualification Survey

Lessons from Pharmaceutical Laboratory related FDA Warning Letters

GMP Track 1 Day 2 Session 1 Vendor Assurance

Inspections, Compliance, Enforcement, and Criminal Investigations

Good Documentation Practices. Documentation Requirements For Regulated Environments

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

MA Compliance Reviews Implications for Manufacturers

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

Hetero Drugs Limited

Brumund Foundry Inc.

Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities

An analysis of quality product defects in the centralised procedure

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013

Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)

Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators

Audit Program Background Definition Management Example Content Risk assessment approach

excipients Setting the Scene

Transcription:

Product Quality Review: Overview and Feedback from Inspection GMP/Market Compliance Information Day October 23 rd 2008 Lorraine Nolan Acting Inspection Manager IMB Slide 1

Scope of Presentation Overview of the PQR and requirements The importance of the PQR Feedback from the IMB Inspection Programme 2006-2008 Overview of common deficiencies Examples of Practice Slide 2

Overview of the PQR & Requirements Finished Product EU GMP requirement implemented from Jan 06. Requirement of Part 1 of EU GMP Chapter 1: Quality Management http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfsen/2005_10_gmp_part1_chap1.pdft. PQR is required to be completed annually and incorporates a review of multiple aspects impacting on the quality of the finished product. Slide 3

Overview of the PQR & Requirements API Manufacture EU Guide to GMP Part II Covering Basic Requirements for Active Substances used as starting materials: Section 2.5 includes the conduct of AQRs for APIs. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfsen/2005_10_gmp_part1_chap1.pdft. Slide 4

Overview of the PQR & Requirements PQR is a regular rolling annual review of all products including the following components:- Starting materials & packaging materials. Critical in-process controls & results. Batches failing to meet specification & investigation of these. Significant deviations/non-conformances & associated investigation including evaluation of the effectiveness of CAPAs implemented. Slide 5

Overview of the PQR & Requirements PQR components continued:- Changes to processes or analytical methods. Variations to MAs submitted/granted/refused including those relevant to 3 rd country markets. Results of the on-going stability programme including adverse trends. Quality related returns, complaints and recalls including associated investigations. Slide 6

Overview of the PQR & Requirements PQR components continued:- Adequacy of implemented CAPAs relating to product process or equipment. Post marketing commitments relating to new MAs and MA variations. Qualification status of relevant equipment & utilities. Technical Agreements to ensure that these are up to date and reflective of current activities. Slide 7

Overview of the PQR & Requirements Similar requirements for APRs for API focussing on:- Critical in-process control and test results. Batches failing to meet specification. Critical deviations/non-conformances & associated investigations. Changes to processes or analytical methods. On-going stability programme. Quality related returns, recall, complaints. Adequacy of CAPAs implemented. Slide 8

Overview of the PQR & Requirements Other Important Requirements Joint Responsibility for evaluation of the PQR by the Manufacturer and the Marketing Authorisation Holder (MAH). Technical agreement between the Manufacturer and MAH. Qualified Person responsible for batch release should ensure the accuracy of the review and for its timely performance. Slide 9

Overview of the PQR & Requirements PQRs Should not be a meaningless listing of data. Should review of all required components including: appropriate summary; evaluation and interpretation of the information available on the manufacturing process. Should have the capability of detecting long term trends. Should not be considered in isolation and should be linked to the findings of previous reviews. Slide 10

The Importance of the PQR Controlling and improving processes and quality. Highlighting areas for focusing resource thereby:- o Decreasing risk of out-of specification results. o Decreasing downtime and increasing productivity. o Decreasing the risk of product recall. o Enhancing regulatory compliance. o Improving communication across all areas including production, engineering, quality and regulatory functions. Enhancement of visibility where aspects of the manufacturing operation are contracted out (production, distribution, testing etc). Improvement of product quality thereby contributing to the protection of public and animal health. Slide 11

Feedback from Inspection IMB commenced review of PQRs during finished product manufacture inspections in 2006. From 2006-2008 No specific critical deficiencies have been issued relating to PQRs. Major Deficiencies have been issued. Majority of deficiencies classified as Others. Slide 12

Feedback from Inspection Major Deficiencies Relate to the absence of an adequate system for performing PQRs and/or significant non-compliance with requirements:- PQRs have not been prepared. PQRs not completed for all products. No interpretation, evaluation or trending of data. Inappropriate grouping of reviews. MAH responsibilities not adhered to. In-appropriate devolution of PQR responsibilities to 3 rd country manufacturers. Contracted manufacturing operations not (adequately) involved. Slide 13

Feedback from Inspection Other Deficiencies Relate to less significant non-adherence with EU GMP requirements which include administrative & technical issues. Administrative No SOPs describing the process for preparing PQRs or process not adequately described. Timelines for completion of the review not met. Review and approval of PQR not documented. Slide 14

Feedback from Inspection Other Deficiencies continued Technical PQRs not including all of EU GMP requirements. Individual aspects of the review not adequately evaluated, reviewed and/or trended. PQR incomplete with respect to detail available from other GMP systems e.g. complaints, deviations etc. MAH review & approval of PQRs not apparent. Technical Agreements not describing responsibilities relating to completion of PQRs. Slide 15

Feedback from Inspection Requirement Practice Examples Critical In Process Controls & Results Minimal Statement that process validated & considered to remain in control More Comprehensive Full discussion of in-process results over the review period. Evaluation of process in consistently achieving required results. Statistical evaluation of this consistency. Trending in comparison to previous reviews. Conclusions relating to revalidation requirements. Slide 16

Feedback from Inspection Requirement Practice Examples Batches Failing to Meet Specification Minimal List of batches failing to meet specification More Comprehensive Full review of batches not meeting specification in review period. Evaluation of underlying causes. Statistical evaluation of significance. Comparison with previous reviews. Conclusions/ CAPAs. Slide 17

Feedback from Inspection Requirement Practice Examples Critical nonconformance/ deviations Minimal List of deviations More Comprehensive Listing of deviations considered to be significant over review period. Overview of assigned cause. Information on trending and CAPAs. Assessment of effectiveness of CAPAs. Comparison of deviation with previous reviews. Discussion of trends. Slide 18

Feedback from Inspection Requirement Practice Examples Changes to Processes & Analytical Methods Minimal List of changes More Comprehensive Overview of all changes to processes & analytical methods. Details of associated change controls. Details of the assessment of any regulatory impact. Details of the status of the implementation of change. Discussion of benefits & improvements. Recommendations. Slide 19

Feedback from Inspection Requirement Practice Examples On-going stability programme Minimal General Statement about the compliance of the on-going stability programme More Comprehensive Overview of the stability data collected over the review period. Discussion of deviations in collated data, including OOS & resultant actions. Evaluation of stability trends or shifts, taking into account evaluation from previous reviews. Conclusions including assessment of the impact of stability trends. Slide 20

Feedback from Inspection Requirement Practice Examples Quality Related Returns, Recall, Complaints Minimal List of returned batches List of Recall batches. List of complaint numbers More Comprehensive Overview of product returned due to quality concerns: Discussion of underlying causes, implications & CAPAs Overview of product recalls: Discussion of underlying causes, implications & CAPAs Overview of quality related complaints; Full discussion of trends, problem batches & CAPAs; Trending with previous reviews. Slide 21

Feedback from Inspection Requirement Practice Examples Assessment of CAPAs Minimal Process validated & considered to remain in control More Comprehensive Focus on CAPAs relating to process & equipment. Focus is on previous review periods but may cover the current review period. Focus on evaluation of the impact of CAPAs and benefits in improving product quality. Recommendations for further CAPAs. May be considered within individual sections of the review. Slide 22

Feedback from Inspection Requirement Practice Examples Inclusion of a summary Minimal No summary of review findings More Comprehensive Include an over-riding summary Overview key observations made. Highlight unexpected results. Highlight recommendations arising from the review. Conclusions with respect to evaluation of the review. Slide 23

Conclusions In summary the PQR should include sufficient discussion and evaluation to allow realisation of the objectives of the review which are Verification of the consistency of the process. Verification of the appropriateness of the specifications for starting materials & finished product. Highlight trends. Identify Improvements. Contribute further to protection of public & animal health. Slide 24